- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Abraxane Capitalizes on the Resurgence of Chemotherapy Combinations in Pancreatic Cancer at ASCO GI 2013
Over the past decade, advances in the understanding of tumor biology and driving mutations have led to the discoveries of numerous biomarkers and targeted agents that have revolutionized the fight against cancer. With recent news being so heavily centered on these targeted agents, it seems as though people often forget about the value that chemotherapy has provided over the years and, more importantly, that there is still room for improvement in these older regimens to generate significantly better outcomes for patients. Celgene was looking to take advantage of this sentiment when the company acquired Abraxis BioScience and their leading drug candidate, Abraxane®, an injectable suspension of nanoparticle albumin bound (nab)-paclitaxel.
Read the full story: http://bit.ly/11eKDS3
Source: Oncology Business Review
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More
